β2-Glycoprotein I/HLA class II complexes are novel autoantigens in antiphospholipid syndrome

Blood

Volumn 125, Issue 18, 2015, Pages 2835-2844

  Tanimura, Kenji ^a,b   Jin, Hui ^a,c   Suenaga, Tadahiro ^a,c   Morikami, Satoko ^b,c   Arase, Noriko ^a,d   Kishida, Kazuki ^a,c   Hirayasu, Kouyuki ^c   Kohyama, Masako ^a,c   Ebina, Yasuhiko ^b   Yasuda, Shinsuke ^e   Horita, Tetsuya ^e   Takasugi, Kiyoshi ^f   Ohmura, Koichiro ^g   Yamamoto, Ken ^h,k   Katayama, Ichiro ^d   Sasazuki, Takehiko ^h   Lanier, Lewis L ⁱ   Atsumi, Tatsuya ^e   Yamada, Hideto ^b   Arase, Hisashi ^a,c,j  

^a OSAKA UNIVERSITY   (Japan)

^b KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c OSAKA UNIVERSITY   (Japan)

^d OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^f Dohgo Spa Hospital   (Japan)

^g KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^h KYUSHU UNIVERSITY   (Japan)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^k KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

More than 80 of patients with aps possess autoantibodies against b2gpi hla class ii complexes; 2gpi complexed with hla class ii molecules was found to be a target for autoantibodies in aps

Indexed keywords

BETA2 GLYCOPROTEIN 1; HLA ANTIGEN CLASS 2; PHOSPHOLIPID ANTIBODY; AUTOANTIBODY; MULTIPROTEIN COMPLEX;

ADULT; AGED; ANTIBODY TITER; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CELL SURFACE; CLINICAL ARTICLE; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; MALE; PATHOGENESIS; PLACENTA TISSUE; PRIORITY JOURNAL; BLOOD; CASE CONTROL STUDY; CELL CULTURE; HEK293 CELL LINE; IMMUNOLOGY; METABOLISM; PREGNANCY; PREGNANCY COMPLICATION; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; AGED; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; AUTOANTIBODIES; BETA 2-GLYCOPROTEIN I; CASE-CONTROL STUDIES; CELLS, CULTURED; FEMALE; HEK293 CELLS; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MULTIPROTEIN COMPLEXES; PREGNANCY; PREGNANCY COMPLICATIONS;

EID: 84928777989     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-08-593624     Document Type: Article

References (60)

1. Wilson WA, Gharavi AE, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum. 1999;42(7):1309-1311.
2. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295-306.
3. Galli M, Comfurius P, Maassen C, et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet. 1990;335(8705):1544-1547.
4. Matsuura E, Igarashi Y, Fujimoto M, Ichikawa K, Koike T. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet. 1990; 336(8708):177-178.
5. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipidbinding inhibitor of coagulation: b 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA. 1990; 87(11):4120-4124.
6. Sakai Y, Atsumi T, Ieko M, et al. The effects of phosphatidylserine-dependent antiprothrombin antibody on thrombin generation. Arthritis Rheum. 2009;60(8):2457-2467.
7. Bohgaki M, Atsumi T, Yamashita Y, et al. The p38 mitogen-activated protein kinase (MAPK) pathway mediates induction of the tissue factor gene in monocytes stimulated with human monoclonal anti-b2Glycoprotein I antibodies. Int Immunol. 2004;16(11):1633-1641.
8. Sikara MP, Routsias JG, Samiotaki M, Panayotou G, Moutsopoulos HM, Vlachoyiannopoulos PG. β2 Glycoprotein I (b2GPI) binds platelet factor 4 (PF4): implications for the pathogenesis of antiphospholipid syndrome. Blood. 2010;115(3): 713-723.
9. Giannakopoulos B, Krilis SA. The pathogenesis of the antiphospholipid syndrome. N Engl J Med. 2013;368(11):1033-1044.
10. Galli M, Barbui T, Zwaal RF, Comfurius P, Bevers EM. Antiphospholipid antibodies: involvement of protein cofactors. Haematologica. 1993;78(1):1-4.
11. Bas de Laat H, Derksen RH, de Groot PG. β2-glycoprotein I, the playmaker of the antiphospholipid syndrome. Clin Immunol. 2004; 112(2):161-168.
12. Caronti B, Calderaro C, Alessandri C, et al. β2-glycoprotein I (β2-GPI) mRNA is expressed by several cell types involved in anti-phospholipid syndrome-related tissue damage. Clin Exp Immunol. 1999;115(1):214-219.
13. Chamley LW, Allen JL, Johnson PM. Synthesis of b2 glycoprotein 1 by the human placenta. Placenta. 1997;18(5-6):403-410.
14. Agar C, van Os GM, Mörgelin M, et al. β2-glycoprotein I can exist in 2 conformations: implications for our understanding of the antiphospholipid syndrome. Blood. 2010;116(8): 1336-1343.
15. de Laat B, Derksen RH, van Lummel M, Pennings MT, de Groot PG. Pathogenic anti-b2-glycoprotein I antibodies recognize domain I of b2-glycoprotein I only after a conformational change. Blood. 2006;107(5):1916-1924.
16. Matsuura E, Igarashi Y, Yasuda T, Triplett DA, Koike T. Anticardiolipin antibodies recognize b 2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface. J Exp Med. 1994;179(2):457-462.
17. Bouma B, de Groot PG, van den Elsen JM, et al. Adhesion mechanism of human b(2)-glycoprotein I to phospholipids based on its crystal structure. EMBO J. 1999;18(19):5166-5174.
18. Schwarzenbacher R, Zeth K, Diederichs K, et al. Crystal structure of human b2-glycoprotein I: implications for phospholipid binding and the antiphospholipid syndrome. EMBO J. 1999; 18(22):6228-6239.
19. Giles IP, Isenberg DA, Latchman DS, Rahman A. How do antiphospholipid antibodies bind b2-glycoprotein I? Arthritis Rheum. 2003;48(8): 2111-2121.
20. Amengual O, Atsumi T, Khamashta MA, Koike T, Hughes GR. Specificity of ELISA for antibody to b 2-glycoprotein I in patients with antiphospholipid syndrome. Br J Rheumatol. 1996;35(12): 1239-1243.
21. Atsumi T, Ieko M, Bertolaccini ML, et al. Association of autoantibodies against the phosphatidylserine-prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulant. Arthritis Rheum. 2000;43(9):1982-1993.
22. Otomo K, Atsumi T, Amengual O, et al. Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events. Arthritis Rheum. 2012;64(2):504-512.
23. Gardiner C, Hills J, Machin SJ, Cohen H. Diagnosis of antiphospholipid syndrome in routine clinical practice. Lupus. 2013;22(1):18-25.
24. Savi M, Ferraccioli GF, Neri TM, et al. HLA-DR antigens and anticardiolipin antibodies in northern Italian systemic lupus erythematosus patients. Arthritis Rheum. 1988;31(12):1568-1570.
25. Hartung K, Coldewey R, Corvetta A, et al; SLE Study Group. MHC gene products and anticardiolipin antibodies in systemic lupus erythematosus results of a multicenter study. Autoimmunity. 1992;13(2):95-99.
26. Domenico Sebastiani G, Minisola G, Galeazzi M. HLA class II alleles and genetic predisposition to the antiphospholipid syndrome. Autoimmun Rev. 2003;2(6):387-394.
27. Granados J, Vargas-Alarcón G, Drenkard C, et al. Relationship of anticardiolipin antibodies and antiphospholipid syndrome to HLA-DR7 in Mexican patients with systemic lupus erythematosus (SLE). Lupus. 1997;6(1):57-62.
28. Neefjes J, Jongsma ML, Paul P, Bakke O. Towards a systems understanding of MHC class I and MHC class II antigen presentation. Nat Rev Immunol. 2011;11(12):823-836.
29. Chicz RM, Urban RG, Gorga JC, Vignali DA, Lane WS, Strominger JL. Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. J Exp Med. 1993;178(1):27-47.
30. Nicholson MJ, Hahn M, Wucherpfennig KW. Unusual features of self-peptide/MHC binding by autoimmune T cell receptors. Immunity. 2005; 23(4):351-360.
31. Meusser B, Hirsch C, Jarosch E, Sommer T. ERAD: the long road to destruction. Nat Cell Biol. 2005;7(8):766-772.
32. Jiang Y, Arase N, Kohyama M, et al. Transport of misfolded endoplasmic reticulum proteins to the cell surface by MHC class II molecules. Int Immunol. 2013;25(4):235-246.
33. Jin H, Arase N, Hirayasu K, et al. Autoantibodies to IgG/HLA class II complexes are associated with rheumatoid arthritis susceptibility. Proc Natl Acad Sci USA. 2014;111(10):3787-3792.
34. Sette A, Adorini L, Colon SM, Buus S, Grey HM. Capacity of intact proteins to bind to MHC class II molecules. J Immunol. 1989;143(4):1265-1267.
35. Castellino F, Zappacosta F, Coligan JE, Germain RN. Large protein fragments as substrates for endocytic antigen capture by MHC class II molecules. J Immunol. 1998;161(8):4048-4057.
36. Sercarz EE, Maverakis E. Mhc-guided processing: binding of large antigen fragments. Nat Rev Immunol. 2003;3(8):621-629.
37. Bottazzo GF, Pujol-Borrell R, Hanafusa T, Feldmann M. Role of aberrant HLA-DR expression and antigen presentation in induction of endocrine autoimmunity. Lancet. 1983;2(8359): 1115-1119.
38. Gottlieb AB, Lifshitz B, Fu SM, Staiano-Coico L, Wang CY, Carter DM. Expression of HLA-DR molecules by keratinocytes, and presence of Langerhans cells in the dermal infiltrate of active psoriatic plaques. J Exp Med. 1986;164(4): 1013-1028.
39. Ballardini G, Mirakian R, Bianchi FB, Pisi E, Doniach D, Bottazzo GF. Aberrant expression of HLA-DR antigens on bileduct epithelium in primary biliary cirrhosis: relevance to pathogenesis. Lancet. 1984;2(8410):1009-1013.
40. Pober JS, Gimbrone MA Jr, Cotran RS, et al. Ia expression by vascular endothelium is inducible by activated T cells and by human g interferon. J Exp Med. 1983;157(4):1339-1353.
41. Collins T, Korman AJ, Wake CT, et al. Immune interferon activates multiple class II major histocompatibility complex genes and the associated invariant chain gene in human endothelial cells and dermal fibroblasts. Proc Natl Acad Sci USA. 1984;81(15):4917-4921.
42. Harris EN, Gharavi AE, Patel SP, Hughes GR. Evaluation of the anti-cardiolipin antibody test: report of an international workshop held 4 April 1986. Clin Exp Immunol. 1987;68(1):215-222.
43. Pengo V, Tripodi A, Reber G, et al; Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. Update of the guidelines for lupus anticoagulant detection. J Thromb Haemost. 2009;7(10):1737-1740.
44. Scott CA, Peterson PA, Teyton L, Wilson IA. Crystal structures of two I-Ad -peptide complexes reveal that high affinity can be achieved without large anchor residues. Immunity. 1998;8(3): 319-329.
45. Ichikawa K, Khamashta MA, Koike T, Matsuura E, Hughes GR. β 2-Glycoprotein I reactivity of monoclonal anticardiolipin antibodies from patients with the antiphospholipid syndrome. Arthritis Rheum. 1994;37(10):1453-1461.
46. Wang J, Shiratori I, Uehori J, Ikawa M, Arase H. Neutrophil infiltration during inflammation is regulated by PILRa via modulation of integrin activation. Nat Immunol. 2013;14(1):34-40.
47. Hayden JB, McCormack AL, Yates JR III, Davey MP. Analysis of naturally processed peptides eluted from HLA DRB1&z.ast;0402 and &z.ast;0404. J Neurosci Res. 1996;45(6):795-802.
48. Koike T, Ichikawa K, Atsumi T, Kasahara H, Matsuura E. β 2-glycoprotein I-anti-b 2-glycoprotein I interaction. J Autoimmun. 2000; 15(2):97-100.
49. Kasahara H, Matsuura E, Kaihara K, et al. Antigenic structures recognized by anti-b2-glycoprotein I auto-antibodies. Int Immunol. 2005; 17(12):1533-1542.
50. Iverson GM, Reddel S, Victoria EJ, et al. Use of single point mutations in domain I of b 2-glycoprotein I to determine fine antigenic specificity of antiphospholipid autoantibodies. J Immunol. 2002;169(12):7097-7103.
51. Söderberg O, Gullberg M, Jarvius M, et al. Direct observation of individual endogenous protein complexes in situ by proximity ligation. Nat Methods. 2006;3(12): 995-1000.
52. Pober JS, Collins T, Gimbrone MA Jr, et al. Lymphocytes recognize human vascular endothelial and dermal fibroblast Ia antigens induced by recombinant immune interferon. Nature. 1983;305(5936):726-729.
53. Riesbeck K, Billström A, Tordsson J, Brodin T, Kristensson K, Dohlsten M. Endothelial cells expressing an inflammatory phenotype are lysed by superantigen-targeted cytotoxic T cells. Clin Diagn Lab Immunol. 1998;5(5): 675-682.
54. Caliz R, Atsumi T, Kondeatis E, et al. HLA class II gene polymorphisms in antiphospholipid syndrome: haplotype analysis in 83 Caucasoid patients. Rheumatology (Oxford). 2001;40(1):31-36.
55. Allen KL, Fonseca FV, Betapudi V, Willard B, Zhang J, McCrae KR. A novel pathway for human endothelial cell activation by antiphospholipid/antib2 glycoprotein I antibodies. Blood. 2012;119(3): 884-893.
56. Cines DB, Pollak ES, Buck CA, et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood. 1998;91(10): 3527-3561.
57. Proulle V, Furie RA, Merrill-Skoloff G, Furie BC, Furie B. Platelets are required for enhanced activation of the endothelium and fibrinogen in a mouse thrombosis model of APS. Blood. 2014; 124(4):611-622.
58. Girardi G, Berman J, Redecha P, et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest. 2003;112(11): 1644-1654.
59. Girardi G, Redecha P, Salmon JE. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med. 2004;10(11):1222-1226.
60. Pierangeli SS, Girardi G, Vega-Ostertag M, Liu X, Espinola RG, Salmon J. Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia. Arthritis Rheum. 2005;52(7):2120-2124.